Promising Blackcurrant Clinical Trial

Breakthrough research into the benefits of blackcurrants for people living with diabetes and metabolic disorders has taken place at the University of Auckland.

IGF-1, is a hormone that promotes the growth of capillaries and new cells, but its levels cannot be directly or artificially increased in the human body. Dr Jian Guan from the University of Auckland made the groundbreaking discovery that the Cyclic Glycine-Proline (cGp) molecule can help control the IGF-1 molecule in human bodies. She then also discovered that South Island Blackcurrants naturally have significantly high amounts of cyclic Glycine-Proline (cGp).

cGPMax is a non-synthetic supplement, that uses cGP from Canterbury Blackcurrants to manage the body's IGF-1 hormone. A clinical trial of cGPMax is about to take place at a university-affiliated hospital in China. Where patients living with diabetes and a range of metabolic syndromes will be monitored for improvement. The trial is looking specifically at the efficiency of the natural cGP on type 2 diabetes associated with dyslipidemia, hypertension, peripheral neuropathy, retinopathy and kidney dysfunction.

Mainstream consumer use of concentrated cGP is still in its infancy, however, there are indications that it can offer hope to people living with a wide range of metabolic disorders. “Should the trial be successful, it is expected to create more export opportunities for the New Zealand made cGPMax supplement in Asian markets like China - where the populations of those with metabolic disorders has risen steadily over the past ten years,” said Dr Guan.

Approximately five percent of kiwis live with type two diabetes, and this is expected to increase to 7 percent in the next twenty years. With the use of natural CGP, the lives of kiwis living with diabetes could be significantly improved.